Lisuride in the treatment of Parkinsonism
- 1 December 1980
- journal article
- research article
- Published by Hindawi Limited in Acta Neurologica Scandinavica
- Vol. 62 (6) , 382-385
- https://doi.org/10.1111/j.1600-0404.1980.tb03050.x
Abstract
Lisuride 1.2–4.8 mg daily was given to 10 patients with severe Parkinsonism for up to 9 months. All had been taking bromocriptine and eight had been taking levodopa combined with carbidopa. Total replacement of bromocriptine by lisuride was achieved in every case, but partial or total levodopa replacement was possible only in five patients. Lisuride 1 mg has approximately the same antiparkinsonian activity as bromocriptine 15 mg or levodopa 250–500 mg combined with carbidopa, but the duration of action of each dose is short, and gastro-intestinal and neuropsychiatric side effects are common. However, lisuride i.v. may be of considerable value in the emergency treatment of severe Parkinsonism.Keywords
This publication has 3 references indexed in Scilit:
- LISURIDE IN PARKINSON'S DISEASEThe Lancet, 1979
- Hypothermic action of lisuride in rats and differences to bromocriptine in the antagonistic effect of neurolepticsNaunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie, 1979
- THE EFFECT OF LISURIDE HYDROGEN MALEATE IN THE HYPERPROLACTINAEMIA-AMENORRHOEA SYNDROME: CLINICAL AND HORMONAL RESPONSESClinical Endocrinology, 1978